Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bonnigheim – page 3

495 clinical trials in Bonnigheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bonnigheim at a glance
495
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

495 trials in Bonnigheim

Open in trial search

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Breast cancer+1

Recruiting

Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Molgramostim
  • Sponsor:Greenwich LifeSciences Inc.

Coeliac disease

Recruiting

Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Vilagletistat
  • Sponsor:Dr. Falk Pharma GmbH

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Effectiveness of PQ Grass for Children and Teens with Seasonal Allergies from Grass Pollen

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Desloratadine
  • Sponsor:Allergy Therapeutics (UK) Limited

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bonnigheim

What the registry says about research in the country

01 Vaccine Development Research

Clinical trials focusing on meningococcal infection prevention through advanced vaccination strategies, specifically evaluating a new quadrivalent conjugate vaccine's long-term effectiveness.

  • Immunogenicity Assessment
  • Booster Dose Evaluation
  • Long-term Protection Studies

This multinational research aims to understand immune persistence and safety profiles in children and adolescents who received initial vaccination as toddlers.

02 Pediatric Immunology

Investigation of immune response patterns in different age groups, from children to adolescents, examining the effectiveness of vaccination schedules over extended periods.

  • Age-specific Response Analysis
  • Seroresponse Monitoring
  • Safety Profile Assessment

The research spans multiple European locations, including Finland, Germany, Spain, and Hungary, ensuring diverse population representation.

03 Preventive Medicine

Comprehensive evaluation of meningococcal disease prevention strategies, focusing on long-term protection through strategic booster dose timing.

  • 5-year Follow-up Studies
  • 10-year Protection Assessment
  • Multiple Serogroup Coverage

This research specifically targets protection against four key meningococcal serogroups: A, C, W, and Y.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.